Our findings appear valuable when compared to a study by Kenmotsu et al. [15], where an Osimertinib-plus-bevacizumab combination failed to exhibit efficacy against Osimertinib monotherapy in improving PFS in patients with non-squamous NSCLC harboring EGFR mutations [15]. Here, EGFR is linked to non-small cell lung carcinoma.